KEGG analysis showed that CCMMs may produce anti-PLC effects via multiple pathways, including pathways in cancer, hepatitis B, PI3K-Akt, TNF, MAPK, hepatitis C, HIF-1, toll-like receptor, and Ras signaling pathway. Here, AKT1 is linked to hepatitis C virus infection.